PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

NCT06742424 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Hepato Cellular Carcinoma (HCC)

Interventions

DRUG: PD-L1 antibody
DRUG: Bevacizumab
PROCEDURE: HAIC-FOLFOX

Sponsor

West China Hospital